2350298-92-7
2350298-92-7 structure
- Name: Penpulimab
- Chemical Name: Penpulimab
- CAS Number: 2350298-92-7
- Molecular Formula:
- Molecular Weight:
- Catalog: Signaling Pathways Immunology/Inflammation PD-1/PD-L1
- Create Date: 2022-09-12 18:05:43
- Modify Date: 2024-01-11 21:05:02
-
Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities[1].
| Name | Penpulimab |
|---|
| Description | Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Penpulimab demonstrates better stability and a lower level of host-cell protein residue compared with IgG4 backbone anti-PD-1 antibodies[1]. Penpulimab does not mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC) and induces no remarkable IL-6 and IL-8 release by activated macrophages[1]. Penpulimab exhibits slower binding off-rate for human PD-1 than Nivolumab (HY-P9903) and Pembrolizumab (HY-P9902)[1]. Penpulimab potentiates T cell activation via PD-1/PD-L1 blockade[1]. |
| In Vivo | Penpulimab (5 mg/kg; i.p.; twice a week, 3weeks) inhibits tumor growth in mice[2]. Animal Model: MC38-hPD-L1 tumor-bearing B-hPD-1 humanized mouse model[2] Dosage: 5 mg/kg Administration: IP, twice a week, 3weeks Result: Showed moderate inhibition of tumor growth (tumor volume: 58.4% of control group). Treatment combined with anlotinib (1 mg/kg, every day, p.o) significantly decreased tumor volume to 36.5% of control group. |
| References |
| No Any Chemical & Physical Properties |